HUTCHMED (China) starts HMPL-A830 trial. HUTCHMED (China) stock gains 2.75 percent

Published on 10/06/2026 at 15:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The first patient received a dose in China on September 24, 2026. HUTCHMED (China) stock costs EUR 13.10 on October 6, 2026 after EUR 12.75.

HCM, US44842L1035, Illustration mit AI erstellt.

HUTCHMED (China) Limited (ISIN US44842L1035) was trading at EUR 13.10 at Lang & Schwarz on October 6, 2026 at 3:10 p.m. CEST, plus 2.75 percent versus the prior close of EUR 12.75. Its Nasdaq listing and ISIN are identified by Global Banking and Finance Review. On September 27, 2026, HUTCHMED announced the start of the Phase Ia global trial of HMPL-A830, with the first patient dosed in China on September 24, 2026, according to GlobeNewswire.

HMPL-A830 enters Phase Ia

The first-in-human study is evaluating safety, tolerability, pharmacokinetics, immune response and preliminary efficacy in patients with advanced or metastatic solid tumors. The dose-escalation stage will determine the maximum tolerated dose and the recommended dose for expansion, while later stages will examine selected tumor types.

HMPL-A830 combines a KRAS inhibitor payload with an antibody targeting EGFR. The approach is aimed at colorectal, pancreatic and lung cancers, giving HUTCHMED a clinical development milestone beyond its marketed oncology portfolio.

GSK deal adds USD 110.0 million

The trial follows HUTCHMED's September 3, 2026 agreement with GSK for development and commercialization rights outside Mainland China, Hong Kong, Macau and Taiwan. The agreement provides USD 110.0 million upfront and potential milestone payments of up to USD 1.2 billion, while HUTCHMED retains responsibility for the global Phase I program, according to GlobeNewswire. The milestone structure makes clinical progress the central financial variable, because most of the potential consideration depends on later development, regulatory and commercial achievements.

First-half revenue reached USD 278.0 million

HUTCHMED reported total revenue of USD 278.0 million in the first half of 2026, while oncology revenue rose 23.00 percent year over year to USD 162.0 million. Ex-US FRUZAQLA sales increased 70.00 percent in that period, and full-year revenue guidance stood at USD 330.0 million to USD 450.0 million, according to ScanX News. Net income was USD 16.0 million in the first half, compared with a prior-year period that included a USD 460.0 million divestment gain, so operating progress and one-time effects must be separated.

HCM trades above its prior close

HUTCHMED stock was trading at EUR 13.10 at Lang & Schwarz on October 6, 2026 at 3:10 p.m. CEST, up 2.75 percent from the Lang & Schwarz prior close of EUR 12.75 on October 5, 2026. The primary Nasdaq quote was USD 14.31 on October 5, 2026 at 4:00 p.m. ET, while the 52-week range was USD 9.77 to USD 16.40 and market capitalization was USD 2.5 billion.